José Luís Blanco
A5100772675- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Hepatitis C virus research
- HIV-related health complications and treatments
- COVID-19 Clinical Research Studies
- Poxvirus research and outbreaks
- HIV, Drug Use, Sexual Risk
- Pneumocystis jirovecii pneumonia detection and treatment
- Bacillus and Francisella bacterial research
- Liver Disease Diagnosis and Treatment
- Reproductive tract infections research
- Hepatitis B Virus Studies
- Sex work and related issues
- Syphilis Diagnosis and Treatment
- Long-Term Effects of COVID-19
- COVID-19 Impact on Reproduction
- Herpesvirus Infections and Treatments
- Biochemical and Molecular Research
- SARS-CoV-2 and COVID-19 Research
- Colorectal and Anal Carcinomas
- COVID-19 and healthcare impacts
- Cervical Cancer and HPV Research
- Drug-Induced Adverse Reactions
- Genital Health and Disease
Universitat de Barcelona
2016-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2025
Hospital Clínic de Barcelona
2016-2025
Centro de Investigación Biomédica en Red
2022-2024
Instituto de Salud Carlos III
2022-2024
Fundació Clínic per a la Recerca Biomèdica
2017-2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2024
Hospital for Tropical Diseases
2022
Barcelona Institute for Global Health
2018-2021
Asociación Colombiana de Neumología y Cirugía de Tórax
2021
Before April 2022, monkeypox virus infection in humans was seldom reported outside African regions where it is endemic. Currently, cases are occurring worldwide. Transmission, risk factors, clinical presentation, and outcomes of poorly defined.
Current therapies for chronic hepatitis C virus (HCV) in HIV co-infected patients have a low success rate and are poorly tolerated. We evaluated the efficacy safety of interferon alfa-2b (IFN) + ribavirin (RBV) versus pegylated (PEG-INF) RBV.Randomized, single-centre, open-label clinical trial including with: detectable HCV-RNA, alanine aminotransferase > 1.5-fold upper limit normal, abnormal liver histology, CD4 cell count 250 x 10/l RNA < 10 000 copies/ml. Patients were assigned to INF (3...
A monkeypox (MPX) outbreak has expanded worldwide since May 2022. We tested 147 clinical samples collected at different time points from 12 patients by real-time PCR. MPX DNA was detected in saliva all cases, sometimes with high viral loads. Other were frequently positive: rectal swab (11/12 cases), nasopharyngeal (10/12 semen (7/9 urine (9/12 cases) and faeces (8/12 cases). These results improve knowledge on virus shedding the possible role of bodily fluids disease transmission.
Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is single-arm, open-label III which therapy-experienced adults with received DTG BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after was optimized ≥1 fully active drug and continued. primary efficacy...
<h2>Summary</h2><h3>Background</h3> Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat prevent HIV, although few data exist frequency risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed do a global assessment after virological failure with first-line...
Since May 2022, a new outbreak of monkeypox has been reported in several countries, including Spain. The clinical and epidemiological characteristics the cases this may differ from those earlier reports.To document current outbreak.We conducted prospective cross-sectional study multiple medical facilities Spain to describe 2022 outbreak.In total, 185 patients were included. Most started with primarily localized homogeneous papules, not pustules, probable area inoculation, which could be...
Objectives To assess the incidence and risk factors for hepatotoxicity associated with nevirapine. Design A prospective cohort study in a teaching referral hospital involving all consecutive patients who were prescribed nevirapine-containing antiretroviral regimen between September 1997 May 2000. Method Cutaneous hepatic adverse reactions clinical hepatitis assessed. Blood analysis including plasma HIV-1 RNA CD4 cell counts, liver chemistry tests, serology B C viruses. Hepatotoxicity was...
Background: Pre-eclampsia and/or fetal death have increased sharply in HIV-infected pregnant women receiving HAART. Methods: The occurrence of pre-eclampsia or was analysed who delivered after at least 22 weeks gestation for all (January 2001 until July 2003) and (November 1985 2003). Results: In 2001, 2002 2003, the rates per 1000 deliveries death, respectively, remained stable 25.4, 31.9 27.7 (P = 0.48) 4.8, 5.8, 5.0 0.89) (n 8768). 1985–2000 390) to 2001–2003 82), rose from 0.0 109.8 <...
Background: It is unclear how characteristics, risk factors, and incidence of coronavirus disease 2019 (COVID-19) in people living with HIV (PLWH) differ from the general population. Methods: Prospective observational single-center cohort study adult PLWH reporting symptoms COVID-19. We assessed clinical factors for COVID-19 diagnosis severity, standardized rate ratio cases Barcelona. Results: From 1 March 2020 to 10 May 2020, 53 out 5683 (0.9% confidence interval 0.7–1.2%) were diagnosed...
Background: Integrase inhibitors have shown better tolerability than other drugs in clinical trials, but some post-marketing data suggested potential differences among them. Aims: We compared rates and reasons for discontinuation of raltegravir-, elvitegravir- dolutegravir-based regimens a large cohort HIV-infected patients. Methods: Retrospective analysis prospectively followed including all antiretroviral-naive virologically suppressed antiretroviral-experienced patients prescribed first...
BackgroundFactors affecting outcomes of SARS-CoV-2 infection in people living with HIV are unclear. We assessed the factors associated diagnosis and severe among HIV.MethodsWe did a retrospective cohort study using data from PISCIS Catalonia (Spain) between March 1 Dec 15, 2020. linked integrated health-care, clinical, surveillance registries through Public Data Analysis for Health Research Innovation Program (PADRIS) to obtain on diagnosis, chronic comorbidities, as well clinical mortality...
Background Antiretroviral therapy has changed the natural history of human immunodeficiency virus (HIV) infection in developed countries, where it become a chronic disease. This clinical scenario requires new approach to simplify follow-up appointments and facilitate access healthcare professionals. Methodology We internet-based home care model covering entire management HIV-infected patients. was called Virtual Hospital. report results prospective randomised study performed over two years,...
Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development the G118R mutation arose following switch from elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine dolutegravir monotherapy. The also in treatment-experienced patient switched genetic basis for selection and potential phenotypic outcome was ascertained. Genotypic analysis performed on patients virological...
BackgroundCalcium is an essential ion for pathogen survival and virulence involved in the regulation of inflammatory response. Hypocalcemia a common laboratory finding critically ill patients. Data regarding levels calcium SARS-CoV-2 infection scarce. Patients with who present hypocalcemia could have worse outcome.MethodsWe performed retrospective analysis hospitalized patients included all had any serum measurement first 72 h since hospital admission. The main objective was to investigate...
The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is mainly based on robust, pivotal clinical trials.To provide data BIC/FTC/TAF in real life.This was an observational, retrospective and single-centre study. We included all adult, treatment-naive (TN) treatment-experienced (TE) people living with HIV (PLWH) starting from 8 June 2018. evaluated effectiveness [on treatment (OT), modified intention-to-treat (mITT) (ITT)], tolerability safety those patients who reached 6...
Abstract Background The use of remdesivir has demonstrated a significant reduction in the time to recovery patients with COVID-19. However, impact on mortality is still controversial. Therefore, it necessary evaluate whether there specific subgroup whom an active antiviral therapy also reduces mortality. Methods Patients admitted for &gt;48 h our hospital SARS-CoV-2 confirmed or suspected infection from February 2020 2021 were retrospectively analysed. primary outcome study was at 30...
Objectives: To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r. Methods: Forty-eight weeks analysis a randomized, open-label, noninferiority trial including with virological suppression (≤200 copies/mL for ≥6 months) on LPV/r-containing triple highly active antiretroviral therapy. Patients (n = 248) were randomized 1:1 either continue LPV/r twice day 127) or switch...